A carregar...
Combined Inhibition of Cyclin-Dependent Kinases (Dinaciclib) and AKT (MK-2206) Blocks Pancreatic Tumor Growth and Metastases in Patient-Derived Xenograft Models
KRAS is activated by mutation in the vast majority of cases of pancreatic cancer; unfortunately, therapeutic attempts to inhibit KRAS directly have been unsuccessful. Our previous studies showed that inhibition of cyclin-dependent kinase 5 (CDK5), reduces pancreatic cancer growth and progression, th...
Na minha lista:
| Publicado no: | Mol Cancer Ther |
|---|---|
| Main Authors: | , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2015
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4497872/ https://ncbi.nlm.nih.gov/pubmed/25931518 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-15-0028 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|